SEC INSIDER TRANSACTIONS

BECTON DICKINSON & CO (BDX) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

BDX · BECTON DICKINSON & CO

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Stale snapshot · Covered: filings 2026-10-15 to 2026-11-13 · 4 filings · fetched 2026-11-13T16:39:22Z

View six-calendar-month insider history →

Recent reported activity

0purchase rows on this page

2sale rows on this page

7matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-11-06Filed 2026-11-10	Byington Carrie LDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The securities convert to common stock on a one-for-one basis. F2 The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. F3 Includes rights acquired through dividend investment since the last report filed by the reporting person. References: F1, F2, F3	A Award / grantRights to Common Stock Under 1996 Directors Deferral Plan · Derivative	79A	197.88	Direct	Form 4 ↗0001628280-26-072778
2026-11-06Filed 2026-11-10	Huffines Robert LutherDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The securities convert to common stock on a one-for-one basis. F2 The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. F3 Includes rights acquired through dividend investment since the last report filed by the reporting person. References: F1, F2, F3	A Award / grantRights to Common Stock Under BD Deferred Compensation Plan · Derivative	158A	197.88	Direct	Form 4 ↗0001628280-26-072781
2026-11-05Filed 2026-11-09	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Award terms reflect the adjustments made in connection with the embecta spinoff and the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F2 The stock appreciation rights vest in four annual installments beginning November 26, 2019. The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References: F1, F2	M Exercise / conversionStock Appreciation Rights · Derivative	20,239D	0	Direct	Form 4 ↗0001628280-26-072360
2026-11-05Filed 2026-11-09	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Award terms reflect the adjustments made in connection with the embecta spinoff and the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F2 The stock appreciation rights vest in four annual installments beginning November 26, 2019. The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References:	S Sale (market/private)Common Stock · Non-derivative	2,993D	210	Direct	Form 4 ↗0001628280-26-072360
2026-11-05Filed 2026-11-09	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Award terms reflect the adjustments made in connection with the embecta spinoff and the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F2 The stock appreciation rights vest in four annual installments beginning November 26, 2019. The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References:	D Other reported codeCommon Stock · Non-derivative	17,246D	210	Direct	Form 4 ↗0001628280-26-072360
2026-11-05Filed 2026-11-09	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Award terms reflect the adjustments made in connection with the embecta spinoff and the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F2 The stock appreciation rights vest in four annual installments beginning November 26, 2019. The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References:	M Exercise / conversionCommon Stock · Non-derivative	20,239A	178.94	Direct	Form 4 ↗0001628280-26-072360
2026-10-26Filed 2026-10-27	Feld MichaelOfficer · EVP, Chief Revenue Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 27, 2026. References:	S Sale (market/private)Common Stock · Non-derivative	76D	198.13	Direct	Form 4 ↗0001628280-26-067525

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.